• In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, while also raising its full-year 2026 revenue guidance range to US$60.5 billion–US$62.5 billion.
• Separately, the European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva’s 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405, a step that could broaden Pfizer’s vaccine portfolio beyond its COVID-19 offerings if the candidate secures approval.
• Now we’ll examine how the EMA’s Lyme vaccine filing milestone may influence Pfizer’s investment narrative centered on pipeline-driven growth.

Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Pfizer Investment Narrative Recap

To own Pfizer today, you really need to believe that its late stage pipeline and recent acquisitions can offset patent expiries and earnings pressure. The EMA’s review of the Lyme vaccine is directionally helpful for that pipeline driven story, but it is not the most important near term catalyst compared with restoring earnings quality after recent impairment charges. Key risks around drug pricing reform and upcoming loss of exclusivity remain unchanged by this news.

In the near term, the most relevant development is Pfizer’s slight raise to its 2026 revenue guidance to US$60.5 billion–US$62.5 billion, despite reporting a Q2 net loss driven by US$4.3 billion of non cash intangible impairments. That guidance update sits in the background as investors think about how a potential Lyme vaccine approval might contribute to future revenue mix, alongside other late stage assets that are expected to help bridge the patent cliff.

Yet investors should also be aware of how these pipeline wins interact with coming patent expirations and pricing pressure risks...

Pfizer's narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This requires a 4.6% yearly revenue decline and an earnings increase of about $1.7 billion from $7.5 billion today.

Uncover how Pfizer's forecasts yield a $29.19 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some analysts were already expecting Pfizer to generate about US$57.5 billion of revenue and US$11.3 billion of earnings by 2029, painting a far more optimistic picture than the consensus view. This Lyme vaccine milestone could either reinforce that bullish pipeline story or prompt those expectations to be revisited, which is why it is worth comparing how differently you and those analysts might weigh the same risks and opportunities.

Explore 18 other fair value estimates on Pfizer - why the stock might be worth 7% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

No Opportunity In Pfizer?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.